Elliot Israel, MD
Pulmonary Disease · Brookline, MANPI 1003891151
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $240,131 of the $292,852 with a category attached, or 82.0%. It is spread thinly across 15 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2019 at $77,518 and has fallen 82.4% since, to $13,628 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $1301.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$70K
- GSK$56K
- Sanofi$47K
- Regeneron Healthcare Solutions, Inc.$34K
- Merck$18K
- Astrazeneca UK Limited$18K
- plus $49K from 9 others
Across 93 payments — averaging $11,624 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$833K
- Sanofi US Services Inc.$178K
- Teva Pharmaceuticals USA, Inc.$46K
- Sanofi$8K
- Amgen$7K
- Novartis$4K
- plus $5K from 2 others
What the payments were for
- Consulting fees$240,13182%
- Speaking & faculty fees$1220%
- Travel & lodging$48,16416%
- Food & beverage$4,4082%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $70,250 |
| GSK | 35 | $56,149 |
| Sanofi | 19 | $46,771 |
| Regeneron Healthcare Solutions, Inc. | 33 | $33,818 |
| Merck | 13 | $18,366 |
| Astrazeneca UK Limited | 13 | $17,998 |
| Amgen | 8 | $16,414 |
| Astrazeneca AB | 4 | $12,000 |
| Novartis | 7 | $7,020 |
| Regeneron | 9 | $6,605 |
| Chiesi USA, Inc. | 2 | $3,500 |
| Sanofi-aventis U.S. LLC | 1 | $2,264 |
| Pfizer | 1 | $1,400 |
| Medical Graphics Corporation | 1 | $161 |
| Genentech USA, Inc. | 1 | $137 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$292,852 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 13 | $1,031 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Brookline
- Sarah GrantBrookline$678K
- Yaron GoldmanWorcester$843K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Adam SmithBurlington$296K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.